BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.32.0//EN
X-ORIGINAL-URL:https://oligotherapeutics.org/
X-WR-CALNAME:Oligonucleotide Therapeutics Society
X-WR-CALDESC:Oligonucleotide Therapeutics Society
X-WR-TIMEZONE:UTC
BEGIN:VTIMEZONE
TZID:UTC
X-LIC-LOCATION:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20260514T075453
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-c1fddedef91770071d03c0302e97a306@oligotherapeutics.org
DTSTART;TZID=UTC:20240919T080000
DTEND;TZID=UTC:20240919T180000
DTSTAMP:20240828T035011Z
CREATED:20240828
LAST-MODIFIED:20240828
PRIORITY:5
SEQUENCE:0
TRANSP:OPAQUE
SUMMARY:mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo
DESCRIPTION:Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease for which oligonucleotide therapeutics, such as short interfering RNA (siRNA), are currently being investigated. We synthesized siRNA cross-reactive to mouse (wild-type) Htt and human (mutant) HTT and found that divalent siRNA sustained lowering of wild-type Htt, but not mutant HTT mRNA expression. However we observed near-complete silencing of both mutant HTT protein and wild-type HTT protein. Subsequent fluorescent in situ hybridization analysis shows that divalent siRNA acts predominantly on cytoplasmic mutant HTT transcripts, leaving clustered mutant HTT transcripts in the nucleus largely intact in treated HD mouse brains.\n
URL:http://oligotherapeutics.org/mrna-nuclear-clustering-leads-to-a-difference-in-mutant-huntington-mrna-and-protein-silencing-by-sirnas-in-vivo/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/webp:https://oligotherapeutics.org/wp-content/uploads/2024/08/09-19-2024.webp
END:VEVENT
END:VCALENDAR